

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,612,032 B2
APPLICATION NO. : 10/564861
DATED : November 3, 2009
INVENTOR(S) : Dmitry Dmitrievich Genkin et al.

Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:


Page 7, (column 11, line 31) - delete "1. A method of treatment for lung carcinoma, and malignant and low differentiated lymphoma, said method comprises a step of introducing a treatment agent into a circulating blood system of a cancer patient diagnosed with at least one of the said cancers and diseases, said treatment agent destroys extracellular DNA in said blood of said cancer patient, wherein said treatment agent used to destroy said extracellular DNA is a DNase enzyme; and wherein said treatment agent is administered in doses and regimens which provide blood plasma DNA-hydrolytic activity, - measured in blood plasma, to exceed 150 Kunitz units per liter of plasma during more than 12 hours in total within 24 hours." and insert -- 1. A method of treating lung carcinoma or malignant and low differentiated lymphoma comprising parenterally administering to a patient in need thereof DNase in doses and regimens which provide blood plasma DNA-hydrolytic activity, measured in blood plasma, to exceed 150 Kunitz units per liter of plasma during more than 12 hours in total within 24 hours. --

Page 7, (column 12, line 10) - delete "2. The method according to claim 1, wherein doses of said treatment are introduced to the patient according to a regime schedule which is carried out continuously for no less than 48 hours." and insert -- 2. The method according to claim 1, wherein said doses of DNase are administered to the patient according to a regime schedule which is carried out continuously for no less than 48 hours. --

Page 7, (column 12, line 14) - delete "3. The method according to claim 1, wherein bovine pancreatic DNase is said agent used to destroy said extracellular DNA, said bovine pancreatic DNase is parenterally introduced in doses ranging from 50,000 Kunitz units to 250,000,000 Kunits units a day for 5-360 days." and insert -- 3. The method according to claim 1, wherein the DNase is bovine pancreatic DNase, and the dose is from 50,000 Kunitz units to 250,000,000 Kunitz units a day for 5-360 days. --

Page 7, (column 12, line 19) - delete "4. A method according to claim 1, wherein human recombinant DNase is used." and insert -- 4. The method according to claim 1, wherein the DNase is human recombinant DNase I. --

Signed and Sealed this
Thirtieth Day of August, 2011



David J. Kappos
Director of the United States Patent and Trademark Office

Page 7, (column 12, line 21) - delete “5. The method according to claim 4, wherein human recombinant DNase I (Domase alpha) is parenterally introduced in doses 1,15 mg/kg-500 mg/kg of body weight daily during 5-360 days.” and insert -- 5. The method according to claim 4, wherein the human recombinant DNase I is administered at a dose of 0.15 mg/kg - 500 mg/kg of body weight daily for 5-360 days. --

Page 7, (column 12, line 25) - delete “6. The method according to claim 1, wherein the treatment is carried out from a diagnosis of the cancer and to a remaining term of the patient’s life.” and insert -- 6. The method according to claim 1, wherein the administering is carried out for the remaining term of the patient’s life. --

Page 7, (column 12, line 28) - delete “7. The method according to claim 1, further including a step of introducing a binding agent into said blood system, said binding agent binds said extracellular DNA, wherein said binding agent is anti-DNA antibodies.” and insert -- 7. The method according to claim 1, further comprising parenterally administering to said patient anti-DNA antibodies. --